No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 18 of the 30 quarters in the window, leaving 12 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 56.8x · 10Y median 37.0x · 73rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-03-16. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-05-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-05-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-03-16.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-03-16. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-05-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T19:13:43.523Z. Latest historical point 2026-05-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Stoke Therapeutics, Inc. (STOK) stock was $24.29 as of Oct 6, 2026, 3:10 PM EDT, down 4.06% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -0.9% · 3-year avg +88.2%/yr · 5-year avg -0.2%/yr
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies.
Biotechnology · Bedford, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.88
Revenue Est.
$8.21M
Last Quarter Results
EPS
$-0.93
vs Estimate
$-0.78
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1STOK | $1.57B | $24.29 | -4.06% | -0.93% | -0.24% | N/A | N/A |
| 2INVA | $1.54B | $20.87 | +1.11% | +17.98% | +4.52% | +6.43% | vs STOK |
| 3SNDX | $1.54B | $17.36 | -2.66% | +14.22% | -0.01% | +1.04% | vs STOK |
| 4OMCL | $1.60B | $35.27 | +1.83% | +11.86% | -26.44% | -0.80% | vs STOK |
| 5KMTS | $1.61B | $27.39 | -3.35% | +14.11% | N/A | N/A | vs STOK |
| 6QURE | $1.61B | $23.21 | +1.80% | -58.31% | -6.16% | +11.17% | vs STOK |
forward FY estimate
N/A
$9.32M
vs Estimate
$4.89M
Consensus Rating
Based on 13 analysts
Average Price Target
$46.46
+91.3% upside
Low
$35.00
Current
$24.29
High
$60.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.03 | $-0.92 | $-0.83 | 8 |
| Quarter ending Dec 2026 | $-1.05 | $-0.97 | $-0.84 | 8 |
| Quarter ending Mar 2027 | $-2.19 | $-0.96 | $-0.17 | 3 |
| Quarter ending Jun 2027 | $-2.21 | $-0.97 | $-0.17 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.90 | $-3.62 | $-3.22 | 10 |
| FY 2027 | $-4.63 | $-3.54 | $-2.62 | 10 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $4.96M | $8.21M | $14.23M | 8 |
| Quarter ending Dec 2026 | $3.91M | $8.21M | $15.06M | 8 |
| Quarter ending Mar 2027 | $2.47M | $6.80M | $13.48M | 4 |
| Quarter ending Jun 2027 | $2.53M | $6.94M | $13.76M | 5 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $24.51M | $32.03M | $44.84M | 9 |
| FY 2027 | $1.96M | $44.83M | $92.47M | 9 |
